AG真人官方

Pharming Group reports second quarter and first half 2025 financial results and provides business update

• Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong 搁鲍颁翱狈贰厂罢庐 and 闯辞别苍箩补庐 revenue growth
• 搁鲍颁翱狈贰厂罢庐 second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribers
• 闯辞别苍箩补庐 (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake
• Second quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024
• Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3K未 pathway hyperactivity, supporting reclassification of VUS patients to APDS and suggesting up to a 100-fold increase in APDS prevalence
• Submitted new drug application for leniolisib for the treatment of APDS in Japan
• 2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 million
• Overall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operations
• Pharming to host a conference call today at 13:30 CEST (7:30 am EDT)
  
  

Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (鈥淧harming鈥� or 鈥渢he Company鈥�) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.

Chief Executive Officer, Fabrice Chouraqui, commented:
鈥淲e鈥檝e delivered a strong second quarter, with 26% total revenue growth and positive operating profit, building further on our momentum. 搁鲍颁翱狈贰厂罢庐 continues to show very significant growth, reflecting its unique value proposition for patients in the on-demand HAE market. We鈥檙e also seeing continued acceleration in 闯辞别苍箩补庐 uptake, with first half 2025 patient growth already surpassing the total for all of 2024. Based on our strong first half performance and prospects for the second half of the year, we are raising our full-year revenue guidance.

The newly published study in the peer-reviewed journal Cell highlights the potential to significantly expand 闯辞别苍箩补庐鈥檚 addressable APDS patient population. The data support reclassifying patients with variants of uncertain significance (VUS) as APDS beginning in the second half of 2025. Notably, the study also suggests APDS prevalence may be up to 100 times higher than previously thought.

In recent months, we鈥檝e made meaningful progress in executing our strategy. We launched 闯辞别苍箩补庐 in the U.K., with the first patients now on commercial therapy, and we submitted a regulatory filing for leniolisib in Japan. Enrollment in both proof-of-concept trials studying leniolisib in larger PID indications is progressing well. Finally, we dosed the first patients in the second wave of the pivotal FALCON clinical trial for KL1333 in primary mitochondrial diseases.
We are working on options to mitigate the impact of recently announced U.S. tariffs. Although some uncertainties remain鈥攕uch as potential tariff exclusions鈥攚e do not expect a material impact on our business.

The strength of our commercial portfolio and advancing pipeline鈥攖argeting significant, underserved markets鈥攃ontinues to validate our long-term strategy. We are also on track to deliver on the previously announced reduction in G&A expenses, enhancing our ability to invest in future growth. I鈥檓 grateful to our teams whose expertise and commitment drive our progress and success.鈥�

Second quarter and first half 2025 highlights

Commercialized assets
搁鲍颁翱狈贰厂罢庐 marketed for the treatment of acute HAE attacks

The strong 搁鲍颁翱狈贰厂罢庐 growth continued in the second quarter of 2025, with revenue of US$80.4 million, a 28% increase compared to the second quarter of 2024. Revenue for the first half of 2025 was US$149.0 million, a 37% increase compared to the same period in 2024.

In the U.S. market, we continue to grow the prescriber and patient base and see strong in-market demand over 10 years post-launch, reflecting 搁鲍颁翱狈贰厂罢庐鈥檚 unique position in the on-demand HAE market. Unit sales volume in the U.S. increased by 27% in the second quarter and 31% in the first half.

闯辞别苍箩补庐 (leniolisib) marketed for the treatment of APDS

闯辞别苍箩补庐 revenue increased to US$12.8 million in the second quarter of 2025, a 15% increase compared to the second quarter of 2024. Revenue for the first half of 2025 was US$23.3 million, a 13% increase compared to the same period in 2024. Unit sales volume increased by 10% in the first half of 2025, primarily due to the increase in patients on paid therapy in the U.S.

The U.S. market contributed 92% of second quarter revenues, while the EU and Rest of World contributed 8%.

As of June 30, 2025, we had 114 patients on paid therapy in the U.S., representing a 25% increase from the 91 patients at the end of the second quarter of 2024. We made strong progress finding, enrolling and transitioning additional patients to paid therapy during the second quarter, increasing the number of patients by 12 versus 6 in the first quarter of this year. The increase of 18 patients during the first half of 2025 exceeded the total increase in patients in 2024. We expect that reclassifications of patients with a variant of uncertain significance, or VUS, to APDS will contribute to additional patient growth beginning in the second half of this year.

In April, we launched 闯辞别苍箩补庐 in the U.K., with the National Institute for Health and Care Excellence (NICE) issuing positive final guidance recommending 闯辞别苍箩补庐 (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for adult and pediatric patients 12 years of age and older. The first patients are now on commercial therapy in the U.K.

APDS patient finding

As of June 30, 2025, we have identified 971 diagnosed APDS patients of all ages globally, including 257 patients in the U.S. Of the identified patients in the U.S., 165 patients are 12 years of age or older and eligible for treatment with 闯辞别苍箩补庐, while 52 are between 4 and 11 years of age and would become eligible pending regulatory approval, demonstrating continued progress identifying additional patients.

VUS patient reclassification and APDS prevalence

There are currently over 1,400 known U.S. patients with a variant of uncertain significance, or VUS, in the PIK3CD and PIK3R1 genes implicated in APDS.

In June, a study performed by researchers at Columbia University was published in the leading peer-reviewed journal Cell, supporting reclassification of VUS patients and expanding the characterization of APDS. The study identified over 100 new variants leading to PI3K未 pathway hyperactivity. Data suggest that VUS patients with these gain-of-function variants should be functionally classified as APDS patients. We expect genetic testing laboratories to utilize these data to independently re-assess VUSs and reclassify patients to APDS in the second half of 2025, adding an additional growth driver for 闯辞别苍箩补庐. We are committed to expanding studies to assess additional variants and estimate that 20% of VUS patients could ultimately be diagnosed with APDS.

By analyzing very large datasets of patients who agreed to have their genetic testing linked to their medical records, the research team at Columbia University also concluded that the real prevalence of APDS may be up to 100 times higher than previously estimated. We are now preparing population-based studies to further investigate the genetic prevalence and clinical phenotype of APDS in the newly identified variants, and to better understand the potential to expand 闯辞别苍箩补庐鈥檚 addressable patient population.

闯辞别苍箩补庐 (leniolisib) development
Leniolisib for APDS

As of June 30, 2025, there are 185 APDS patients in either a leniolisib Expanded Access Program (compassionate use), an ongoing clinical study, or a named patient program.

Pediatric label expansion

We remain on track to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS in the third quarter of 2025. An approval decision from the FDA is expected in the first half of 2026.

Japan

In June 2025, we submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of leniolisib for the treatment of APDS in adult and pediatric patients 4 years of age and older. A decision from the PMDA is expected in nine months based on priority review of the application, due to orphan drug designation (ODD) granted by the Ministry of Health, Labour and Welfare of Japan (MHLW) for the treatment of APDS.

European Economic Area (EEA)

We are on track to complete the manufacturing activities requested by the European Medicines Agency鈥檚 (EMA) Committee for Human Medicinal Products (CHMP) as part of the ongoing review of the leniolisib Marketing Authorisation Application (MAA) for APDS patients 12 years of age and older, and to submit a response by the January 2026 deadline.

Leniolisib for additional primary immunodeficiencies (PIDs)

Two Phase II clinical trials are evaluating leniolisib for additional primary immunodeficiencies, or PIDs, which affect significantly more patients than APDS. These include (i) genetically identifiable PIDs with immune dysregulation linked to altered PI3K未 signaling and (ii) common variable immunodeficiency, or CVID, with immune dysregulation identified independently of genetics. We continue to anticipate trial read-outs in 2026.

KL1333 for mitochondrial DNA-driven primary mitochondrial disease

KL1333 is currently in a pivotal clinical trial in primary mitochondrial diseases and has the potential to significantly enhance our future growth. We continue to anticipate trial read-out in 2027 with potential FDA approval by end of 2028.

The pivotal FALCON clinical trial is evaluating KL1333 in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. The FALCON clinical trial is proceeding as planned with additional clinical sites now active and the first patients in wave two of the trial having been dosed.

Acquisition of Abliva AB

In the period from February 14, 2025, to June 18, 2025, Pharming acquired the remaining 11.1% interest in the voting shares of Abliva, thereby increasing its ownership to 100%.

Organizational updates

On May 8, 2025, we announced a plan to reduce our general and administrative (G&A) expenses by 15% or US$10 million to optimize capital allocation to drive sustainable growth of our business. Work is on track to deliver on this objective.

Financial Summary

Financial highlights
Second quarter 2025

For the second quarter of 2025, revenues increased by US$19.1 million, or 26%, to US$93.2 million, compared to US$74.1 million in the second quarter of 2024. 搁鲍颁翱狈贰厂罢庐 revenues amounted to US$80.4 million, a 28% increase compared to the second quarter of 2024. The increase in 搁鲍颁翱狈贰厂罢庐 revenues was primarily driven by an increase in volume. 闯辞别苍箩补庐 revenues amounted to US$12.8 million in the second quarter of 2025, a 15% increase compared to the second quarter of 2024. This increase in 闯辞别苍箩补庐 revenues was primarily driven by an increase in price, enhanced by gross-to-net adjustments that were elevated in the prior year.

Gross profit increased by US$18.1 million, or 27%, to US$84.2 million, compared to US$66.1 million in the second quarter of 2024, mainly due to the increase in revenues.

The operating profit amounted to US$10.8 million compared to an operating loss of US$3.1 million in the second quarter of 2024. Adjusted to exclude US$2.1 million of non-recurring Abliva acquisition-related expenses, of which US$1.9 million is included in General and administrative expenses and US$0.2 million is included in Research and development expenses, the operating profit amounted to US$12.9 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses including US$2.1 million in non-recurring Abliva acquisition-related expenses.

The net finance result amounted to a loss of US$4.0 million compared to a gain of US$3.4 million in the second quarter of 2024. This decline was mainly driven by the absence of a one-time fair value gain recognized in the second quarter of 2024 following the reclassification of the convertible bond-related derivative to equity, as well as by unfavorable EUR/USD exchange rate movements in the second quarter of 2025.

The Company had a net profit of US$4.6 million, compared to a net loss of US$1.2 million in the second quarter of 2024. The change was primarily driven by increased revenues, partially offset by higher operating expenses and a change in the net finance result.

Cash generated from operations amounted to US$11.7 million, compared to US$13.2 million used in operations in the second quarter of 2024. Cash and cash equivalents, including restricted cash and marketable securities, increased from US$108.9 million at the end of first quarter of 2025 to US$130.8 million at the end of the second quarter of 2025. This increase was primarily driven by the net cash flows generated from operating activities.

First half year 2025

Total revenues increased 33% during the first half of 2025 to US$172.3 million, compared to US$129.7 million during the first half of 2024. For the first half of 2025, total 搁鲍颁翱狈贰厂罢庐 revenues were 37% higher at US$149.0 million, compared to revenues of US$109.0 million for the first half of 2024. The increase in 搁鲍颁翱狈贰厂罢庐 revenues was primarily driven by an increase in volume. 闯辞别苍箩补庐 revenues amounted to US$23.3 million in the first half of 2025, a 13% increase compared to the second half of 2024. This increase in 闯辞别苍箩补庐 revenues was primarily driven by an increase in volume.

Gross profit increased by US$41.7 million, or 37%, to US$155.0 million, compared to US$113.3 million in the first half of 2024, mainly due to the increase in revenues.

Further details on revenue and gross profit segmentation is provided in Note 7. Segment information in the Notes to the condensed consolidated interim financial statements of this press release.

The operating profit amounted to US$3.8 million compared to an operating loss of US$19.4 million in the first half of 2024. Adjusted to exclude US$9.9 million of non-recurring Abliva acquisition-related expenses, of which US$7.6 million is included in General and administrative expenses and US$2.3 million is included in Research and development expenses, the operating profit amounted to US$13.7 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses which include a total of US$15.0 million Abliva-related expenses.

The net finance result amounted to a loss of US$8.5 million compared to a gain of US$3.6 million in the first half of 2024. This decline was mainly driven by the absence of a one-time fair value gain recognized in the second quarter of 2024 following the reclassification of the convertible bond-related derivative to equity, as well as by unfavorable EUR/USD exchange rate movements in the first half of 2025.

The Company had a net loss of US$10.3 million, compared to a net loss of US$13.7 million in the first half of 2024. The change was primarily driven by increased revenues, partially offset by a change in the net finance result and higher operating expenses, including US$9.9 million non-recurring Abliva acquisition-related expenses, most of which were not tax-deductible.

Cash generated from operations amounted to US$12.0 million, compared to US$20.9 million used in operations in the first half of 2024. Cash and cash equivalents, including restricted cash and marketable securities, decreased by US$38.6 million to US$130.8 million from US$169.4 million at the end of 2024, primarily driven by purchases of Abliva shares totaling US$66.1 million and non-recurring Abliva acquisition-related expenses totaling US$9.9 million.

Outlook/Summary
For 2025, the Company anticipates:

• Total revenues between US$335.0 million and US$350.0 million (13% to 18% growth), with quarterly fluctuations expected.
• Total operating expenses between US$304.0 million and US$308.0 million, assuming constant currency and US$10.2 million non-recurring Abliva-related transaction and integration expenses.
• Significant progress finding additional APDS patients in the U.S., supported by VUS validation efforts and subsequently converting patients to paid 闯辞别苍箩补庐 (leniolisib) therapy.
• Increasing ex-U.S. revenues for leniolisib - driven by funded access programs and commercial availability in the U.K.
• Progress towards additional regulatory approvals for leniolisib for APDS patients 12 years of age or older, and submitting regulatory filings in Japan and for pediatric label expansion in key global markets.
• Advancing the two ongoing Phase II clinical trials in PIDs with immune dysregulation to significantly expand the long-term commercial potential of leniolisib.
• Advancing the ongoing pivotal FALCON clinical study for KL1333 in mitochondrial DNA-driven primary mitochondrial disease.
• Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases.

No further specific financial guidance for 2025 is provided.

Additional information
Presentation

The conference call presentation is available on the Pharming.com website from 07:30 CEST today.

Conference Call

The conference call will begin at 13:30 CEST/07:30 EDT on Thursday, July 31. A transcript will be made available on the Pharming.com website in the days following the call.听
Please note, the Company will only take questions from dial-in attendees.

Webcast Link:

Conference call dial-in details:

Additional information on how to register for the conference call/webcast can be found on the
Pharming.com website.

Financial Calendar 2025

3Q 2025 financial results听听听听听听听听听听听听听听听听听听听听听听听听November 6

For further public information, contact:

Pharming Group N.V., Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E:

FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E:

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on .

Auditor鈥檚 involvement

The Condensed Consolidated Interim Financial Statements have not been audited by the Company鈥檚 statutory auditor.

Responsibility Statement

The Board of Directors of the Company (the 鈥淏oard鈥�) hereby declares that to the best of its knowledge, the condensed consolidated interim financial statements, which have been prepared in accordance with IAS 34 (interim financial reporting), give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company, and this interim Board report includes a fair review of the information required pursuant to section 5:25d(8) and (9) of the Dutch Financial Supervision Act (Wet op het financieel toezicht).

Leiden, July 31, 2025

Fabrice Chouraqui, Chief Executive Officer and Executive Director
Richard Peters, Non-Executive Director and Chairman of the Board of Directors
Mark Pykett, Non-Executive Director
Barbara Yanni, Non-Executive Director
Leonard Kruimer, Non-Executive Director
Jabine van der Meijs, Non-Executive Director
Elaine Sullivan, Non-Executive Director

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management鈥檚 current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as 鈥渁im鈥�, 鈥渁mbition鈥�, 鈥樷�榓nticipate鈥欌��, 鈥樷�榖elieve鈥欌��, 鈥樷�榗ould鈥欌��, 鈥樷�榚stimate鈥欌��, 鈥樷�榚xpect鈥欌��, 鈥樷�榞oals鈥欌��, 鈥樷�榠ntend鈥欌��, 鈥樷�榤ay鈥欌��, 鈥渕ilestones鈥�, 鈥樷�榦bjectives鈥欌��, 鈥樷�榦utlook鈥欌��, 鈥樷�榩lan鈥欌��, 鈥樷�榩robably鈥欌��, 鈥樷�榩roject鈥欌��, 鈥樷�榬isks鈥欌��, 鈥渟chedule鈥�, 鈥樷�榮eek鈥欌��, 鈥樷�榮hould鈥欌��, 鈥樷�榯arget鈥欌��, 鈥樷�榳ill鈥欌�� and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Pharming Group N.V.

Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)

For the period ended June听30, 2025

• Condensed consolidated interim statement of income
• Condensed consolidated interim statement of comprehensive income
• Condensed consolidated interim balance sheet
• Condensed consolidated interim statement of changes in equity
• Condensed consolidated interim statement of cash flow
  
  

听听

听听

Notes to the condensed consolidated interim financial statements
For the period ended June听30, 2025

1.听听听Company information

Pharming Group N.V. is a limited liability public company which is listed on Euronext Amsterdam (PHARM) and on the NASDAQ (PHAR), with its headquarters and registered office located at:

Darwinweg 24

2333 CR Leiden

The Netherlands

2.听听听Statement of compliance

The consolidated interim financial statements for the six-month period ended June听30, 2025, have been prepared in accordance with International Accounting Standard IAS 34, Interim financial reporting. The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended December听31, 2024, which have been prepared in accordance with International Financial Reporting Standards (EU-IFRS) and IFRS interpretations committee (IFRS IC) interpretations applicable to companies reporting under IFRS as issued by the International Accounting Standards Board (IASB) and valid as of the balance sheet date.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on July听30, 2025.

The published figures in these condensed consolidated interim financial statements are unaudited.

3.听听听Accounting policies

Accounting policies are consistent with those of the financial statements for the year ended December听31, 2024. The following exchange rates have been applied:

4.听听听Estimates and judgements

The preparation of interim financial statements in conformity with IAS 34 and Book 2 Title 9 of the Dutch Civil Code requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company鈥檚 accounting policies. In preparing these condensed consolidated interim financial statements, the significant judgements made by management in applying the Company鈥檚 accounting policies were the same as those applied to the consolidated financial statements for the year ended December听31, 2024.

5.听听听Going concern

In preparing and finishing the interim financial statements the Board of Directors of Pharming have assessed the Company鈥檚 ability to fund its operations for a period of at least twelve months after the date the interim financial statements are issued. Based upon the assessment on a going concern basis, the Company has concluded that funding of its operations for a period of twelve months, after the date the interim financial statements are issued, is realistic and achievable. Overall, based on the outcome of this assessment, the interim financial statements have been prepared on a going concern basis.

6.听听听Seasonality of operations

Seasonality has no material impact on Company鈥檚 interim financial statements.

7.听听听Business combinations and acquisitions of non-controlling interests: Acquisition of Abliva AB

On February听14, 2025, the Group acquired 88.9% of the voting shares of Abliva AB (鈥淎bliva鈥�), a listed company based in Sweden. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease. Pharming acquired Abliva to further strengthen the clinical pipeline with the addition of a therapy, with U.S. launch expected in 2028, aligning with our vision to become a leading global rare disease company. By June听18, 2025, Pharming obtained 100% of the shares of Abliva. This disclosure provides the financial information relating to the business combination.

At initial recognition, Pharming elected to measure the non-controlling interests in Abliva as a proportionate share of the identifiable assets.

Assets acquired and liabilities assumed

The fair values of the identifiable assets and liabilities of Abliva as at the date of acquisition were:

Abliva鈥檚 lead product, KL1333, a regulator of the essential co-enzymes NAD鈦� and NADH, is in a pivotal clinical study (FALCON) in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. Over 30,000 patients diagnosed with mtDNA mitochondrial disease would be potentially addressable by KL1333 in the U.S., EU4 (France, Germany, Italy, Spain) and the UK. KL1333 has shown positive clinical effects in a proof-of-concept Phase 1b study, and a pre-planned interim analysis of the ongoing pivotal FALCON trial demonstrated promising differences over placebo in both alternate primary efficacy endpoints. KL1333 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of PMD in the U.S. and EU.

The investment in equity instruments designated at fair value through other comprehensive income (FVTOCI) comprises 84,444 shares in Isomerase Therapeatics Limited (鈥淚somerase鈥�), representing approximately 10% of Isomerase鈥檚 total outstanding shares. Isomerase is a U.K.-based synthetic biology firm and a strategic partner of Abliva AB. As Isomerase is a privately held company, the investment is classified within Level 3 of the fair value hierarchy. The fair value measurement is based on an assessment of the recoverable amount, estimated using a value-in-use approach. This involves projecting future cash flows in line with the company's internal business plans and forecasts. The valuation also incorporates key assumptions, including discount rates and long-term growth rates beyond the forecast period.

Trade and other receivables primarily comprise short-term investments of surplus cash, placed in interest-bearing deposits with original maturities of three to nine months. These deposits matured in February 2025, at which point the funds were received as cash.

The deferred tax liability mainly arises from the recognition of the intangible asset KL1333, reflecting the associated tax effects.

Loss before tax generated by Abliva and included in the consolidated Statement of Income from February听14, 2025 to June听30, 2025 was US$12.5 million. If the combination had taken place at the beginning of the year, the loss before tax for the Group would have been US$5.1 million. Abliva did not contribute any revenue during 2025.

Acquisition of remaining interest in Abliva

In the period from February 14, 2025, to June 18, 2025, Pharming acquired the remaining 11.1% interest in the voting shares of Abliva, thereby increasing its ownership to 100%. A cash consideration of US$7.0 million was paid to the non-controlling shareholders. The carrying amount of the acquired non-controlling interest was US$5.0 million. The difference of US$2.0 million, has been recognized directly in accumulated deficit in equity. Following the acquisition of the remaining interest in Abliva, the total consideration in cash amounts to US$67.1 million in 2025 based on the price of SEK 0.45 paid per share.

Analysis of cash flows on acquisition

Acquisition-related costs of US$9.7 million were expensed in the period and included within other operating costs in the Consolidated Statement of Income. Moreover, acquisition-related costs of US$1.0 million were expensed in the year ended December 31, 2024 related to this acquisition. Of these additional cost, an amount of US$0.2 million was incurred but unpaid per June 30, 2025. In addition, with respect to the acquisition of the non-controlling interest, a remaining cash outflow of US$1.9 million is expected to occur in the second half year of 2025.

8.听听听Segment information

Operating segments are components of the Company that engage in business activities from which it may incur expenses, for which discrete financial information is available and whose operating results are evaluated regularly by the Company鈥檚 Chief Operating Decision Maker (鈥淐ODM鈥�) to make decisions about resources to be allocated to the segment and assess its performance. The Executive Members of the Board of Directors are considered the CODM.

CODM reviews the Company鈥檚 results under four operating segments based on a combination of the products that the Company has launched - 搁鲍颁翱狈贰厂罢庐 and 闯辞别苍箩补庐, and the main geographies where sales are consummated - focused on the US and reporting, in aggregate, EU and Rest of the World (鈥淩oW鈥�). The four operating segments correspond to each of its four reportable segments for financial reporting purposes.

The CODM reviews revenues and gross profit to assess the performance of their operating segments. The CODM does not review financial information on a segmental basis below gross margin, and balance sheet information is not allocated to the company's reportable segments. There are no intersegment sales.

Total revenues and gross profit per each operating and reportable segment for the period ended June 30 are:

9.听听听Other income

Other income increased by US$0.9 million in the first half of 2025 to US$2.2 million as compared to US$1.3 million the first half of 2024.

10.听听听Expenses by nature

Costs of sales

Costs of inventories recognized as expenses in the first half year of 2025 were US$13.2 million versus US$10.7 million for the first half of 2024 and relates to actual product sales of 搁鲍颁翱狈贰厂罢庐 and 闯辞别苍箩补庐.

Pharming expensed royalty fees to Novartis on 闯辞别苍箩补庐 sales, amounting to US$2.4 million in the first half of 2025 (first half of 2024: US$2.5 million).

Obsolete inventory impairments amounted to US$1.7 million (1H 2024: US$3.1 million) and stems from the valuation of the inventories against lower net realizable value and mainly relates to products no longer eligible for commercial sales.

Other operating costs

Other operating costs increased to US$153.4 million in the first half of 2025 compared to US$134.0 million in the first half year of 2024.

Employee benefits are charged to research and development costs, general and administrative costs, or marketing and sales costs based on the nature of the services provided. Employee benefits of production related employees have been included in the value of inventories.

Depreciation and amortization charges amounted to US$5.3 million in the first half of 2025 compared to US$5.6 million the first half year of 2024, and related to the following:

11.听听听Finance income (expenses)

Foreign currency results mainly stem from fluctuations in the EUR/USD exchange rate. The euro got stronger during the first half of 2025 where it weakened during the first half of 2024. This impacts the revaluation of the bank balances in US dollars incorporated in euro functional currency entities and the receivables and payables in euro incorporated in our USD functional currency entity.

Interest income declined due to lower prevailing interest rates and a reduced overall cash position following the acquisition of Abliva.

12.听听听Income tax (expenses)

Income tax expenses are recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year.

The deferred tax assets increased primarily due to the inclusion of the current period's net operating loss carryforward, partially offset by the effect of temporary differences.

13.听听听Investments

Investments accounted for using the equity method

The asset relates to an investment in the ordinary shares of BioConnection Investments B.V. (鈥淏ioConnection鈥�). In the Board of Directors鈥� judgement, the investment in BioConnection constitutes an investment in an associated company and is therefore not consolidated. Pharming has significant influence but does not have control of BioConnection and is embargoed by a shareholder鈥檚 agreement between the shareholders of BioConnection from influencing any activity between the two parties which is in any significant way different from the relationship which existed between the two prior to the investment.

The carrying amount of this investment has changed as follows:

During the first half year of 2025, we have contributed US$0.4 million to BioConnection, to further strengthen its financial position.

Investment in debt instruments designated as at FVTPL

The asset relates to the preference share in BioConnection Investments B.V. The Board of Directors made an assessment on the accounting treatment of the preference share obtained. The Board concluded that the asset should be recognized as a financial asset (debt instrument) measured at initial recognition at fair value, subsequently measured at fair value through profit and loss. The fair value is calculated on a yearly basis using the forward-looking Black-Scholes-Merton (鈥淏SM鈥�) financial instrument pricing framework. No events or matters are known as of the date of this report which would lead to a significant impact in the fair value of the asset, compared to December听31, 2024.

The carrying amount of this investment has changed as follows:

Investment in equity instruments designated as at FVTOCI

In 2024, the investment related to an equity interest in Orchard Therapeutics, which was subsequently disposed of following a takeover.

In 2025, Pharming acquired 84,444 shares in Isomerase as part of the acquisition of Abliva AB. This holding represents approximately 10% of the total issued shares of Isomerase. As Isomerase is privately held and its shares are not publicly traded, the fair value of the investment is determined annually using using a value-in-use approach as described in note 7.

The carrying amount of investments in equity instruments designated as at FVTOCI has changed as follows:

14.听听听Deferred tax assets

The deferred tax asset increased mainly due to the addition of the current year loss to the DTA for net operating losses.

15.听听听Inventories

Inventories include batches of 闯辞别苍箩补庐 and 搁鲍颁翱狈贰厂罢庐 and relating work in progress which are available for production.

Changes in the adjustment to net realizable value:

The inventory valuation at June听30, 2025, of US$63.7 million (December听31, 2024: US$55.7 million) is stated net of an impairment of US$13.3 million (December听31, 2024: US$8.7 million). The impairment includes impairment for obsolescence and impairment to write inventories down to their net realizable value.

Inventories are available for use in commercial, preclinical and clinical activities. Estimates have been made with respect to the ultimate use or sale of product, taking into account current and expected sales as well as preclinical and clinical programs. These estimates are reflected in the additions to the impairment. The costs of vials used in preclinical and clinical programs are presented under the research and development costs.

The main portion of inventories at June听30, 2025, have expiration dates starting beyond 2025 and are all expected to be sold and/or used before expiration.

16.听听听Marketable securities

Marketable securities consist of euro-denominated SEC Rule 2a-7 compliant institutional money market funds, which offer enhanced financial flexibility compared to government treasury certificates. The marketable securities are measured at amortized costs and amount to US$33.9 million as of June听30, 2025 (December听31, 2024: US$112.9 million). This includes accrued interest of US$0.1 million as of June听30, 2025 (December听31, 2024: US$0.7 million). The decrease in marketable securities is primarily attributable to the acquisition of Abliva AB, as further detailed in note 7.

17.听听听Restricted cash, cash and cash equivalents

Cash is free at disposal of the Company, except for restricted cash. Restricted cash (non-current) includes a deposit for rent which is considered long-term.

For purposes of the cash flow statement, restricted cash is not considered as ''cash and cash equivalents''.

18.听听听Equity

The Company鈥檚 authorized share capital amounts to 鈧�10.6 million (US$12.5 million) and is divided into 1,056,000,000 ordinary shares with a nominal value of 鈧�0.01 each. All 685,147,615 shares outstanding at June听30, 2025, have been fully paid-up. Other reserves include those reserves related to currency translation, share-based compensation expenses and other equity-settled transactions.

Please refer to the Condensed consolidated interim statement changes in Equity.

The other reserves are made up as shown in the below table.

19.听听听Convertible bonds

In April 2024, the Company issued 鈧�100.0 million (US$118.1 million, based on the EUR/USD exchange rate as of June听30, 2025) aggregate principal amount of 4.50% convertible bonds due 2029.

The movements of the convertible bonds were as follows:

20.听听听Earnings per share and diluted shares

Basic earnings per share is calculated based on the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share in the case of a profit is computed based on the weighted average number of ordinary shares outstanding including the dilutive effect of shares to be issued in the future under certain arrangements such as option plans. However, as the net result represents a loss, the diluted earnings per share are equal to the basic earnings per share. For 1H 2025 and 1H 2024, the basic and diluted earnings per share are:

Diluted shares

The composition of the number of shares and share rights outstanding as well as authorized share capital as per June听30, 2025 is provided in the table below:

21.听听听Financial risk management and fair value

Financial risk management

Pharming is exposed to several financial risks: market risks (being currency risk and interest rate risk), credit risks and liquidity risks. The Board of Directors and the Executive Committee are responsible for the management of currency, interest, credit and liquidity risks and as such ultimately responsible for decisions taken in this field. The Group鈥檚 exposure to financial risks has not materially changed during the period.

Fair value

For the convertible bond, lease liabilities, trade payables and other liabilities, the carrying amount is a reasonable approximation of fair value. During the six-month period ended June听30, 2025, there have been no changes related to the fair value hierarchy.

22. Related party transactions

There are no material changes in the nature, scope, and scale in this reporting period compared to last year. More information is included in note 24 to the consolidated financial statements as at and for the year ended December听31, 2024.

23. Events since the end of the reporting period

There were no significant events since the end of the reporting period.

Attachment